The ultimate aim of the study is to enhance the Canadian public’s confidence in vaccine safety.

Study Description

The Canadian Cardiovascular Society (CCS) National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) is a multi-centre study funded by the Public Health Agency of Canada. MYCOVACC is assessing the outcomes of adult and pediatric patients with myocarditis and/or pericarditis following mRNA vaccination for up to three years.

CEBI’s Role

CEBI developed guides for health care provider and patient stakeholder consultations, reviewed evidence updates, drafted an evidence-based care management algorithm for providers, and created a patient information sheet. The current evidence update, care algorithm and patient information sheet are now available on the CCS website: MYCOVACC – Canadian Cardiovascular Society (ccs.ca).

For more information about this work, please contact CEBI by email at cebi@hhsc.ca.